Vivoryon Therapeutics N.V. Reports Q3 2025 Financial Results and Business Updates New analysis of data from varoglutamstat Phase 2 program for patients with lower baseline eGFR shows consistent and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback